Welcome to our dedicated page for Heartflow news (Ticker: HTFL), a resource for investors and traders seeking the latest updates and insights on Heartflow stock.
Heartflow, Inc. develops AI-enabled software for non-invasive detection and management of coronary artery disease. Its updates center on the Heartflow Platform and related analyses, including Heartflow FFRCT Analysis, Heartflow Plaque Analysis and Heartflow Roadmap Analysis, which use coronary CT imaging and software-based interpretation to support cardiovascular care.
Recurring news includes quarterly results, account adoption, payer coverage and reimbursement for Plaque Analysis, clinical evidence presented at cardiology meetings, patient registries such as GAMEFILM and NAVIGATE-PCI, investor conference activity, intellectual property enforcement and additions to Heartflow’s product platform such as PCI Navigator.
Heartflow (Nasdaq: HTFL) will present late-breaking clinical and economic data on its AI-driven Heartflow Plaque Analysis at the American Heart Association Scientific Sessions 2025 in New Orleans, Nov 7–10.
The featured late-breaking presentation, “Coronary CT Angiography Plaque as a Predictor of Death, Cardiovascular Death and Myocardial Infarction,” is scheduled for Nov 9, 12:30 p.m. CST. Heartflow will present seven abstracts, including FISH&CHIPS and PRECISE trial analyses, cost-effectiveness modeling, population plaque-volume trends over seven years, and secondary analyses from REVELUTION.
Note: Heartflow Plaque Analysis is FDA-cleared; Heartflow Plaque Staging is investigational.
Heartflow (Nasdaq: HTFL) will release third quarter 2025 financial results after market close on Wednesday, November 12, 2025.
Management will host a conference call to discuss results starting at 1:30 p.m. PT / 4:30 p.m. ET on November 12, 2025. Interested participants must register online to receive dial-in numbers and a unique PIN; registrants are encouraged to sign up more than 15 minutes before the call. A live and archived webcast will be available in the Investor Relations section of Heartflow's website at https://ir.heartflow.com/.
Heartflow (Nasdaq: HTFL) introduced PCI Navigator, an AI-driven CT-guided PCI planning tool that combines patient-specific 3D anatomy, plaque composition and lesion-specific physiology in a single web-based view to help plan stent placement.
New PLAN CALCIUM data (TCT 2025) found that adding AI plaque analysis to coronary CTA/FFRCT altered calcium modification plans in >50% of lesions. Heartflow will launch the NAVIGATE-PCI registry in 2026 to enroll ~2,500 patients across ~30 U.S. sites, with broader commercial availability planned later in 2026.
Heartflow (NASDAQ: HTFL) has achieved a significant milestone with FDA 510(k) clearance for its Next Gen Heartflow Plaque Analysis algorithm. The AI-powered platform demonstrates 95% agreement with IVUS gold standard and shows a 21% improvement in plaque detection compared to its first-generation algorithm.
The enhanced platform features an advanced 3D color-coded visualization system and an expanded nomogram powered by data from 273,000 patients. Additionally, Cigna will provide nationwide coverage for Heartflow Plaque Analysis across all its business lines starting October 2025, becoming the second major insurer after UnitedHealthcare to align with EviCore guidelines.
The DECIDE Registry data revealed that Heartflow Plaque Analysis led to medical management changes in over 50% of patients and an expected 15% reduction in cardiac events.
Heartflow (Nasdaq: HTFL), a leader in AI-powered coronary artery disease technology, has announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference. The company's management will engage in a fireside chat scheduled for September 10, 2025, at 6:15 a.m. PT / 9:15 a.m. ET.
Investors can access both live and archived versions of the presentation through Heartflow's Investor Relations website at ir.heartflow.com.
Heartflow (NASDAQ: HTFL), an AI technology company focused on coronary artery disease (CAD), has successfully completed its upsized Initial Public Offering (IPO). The company sold 19,166,667 shares at $19 per share, including the full exercise of the underwriters' option to purchase additional 2,500,000 shares.
The IPO generated total gross proceeds of approximately $364.2 million before deducting underwriting discounts and other expenses. Trading of Heartflow's common stock began on the Nasdaq Global Select Market on August 8, 2025. The offering was jointly managed by J.P. Morgan, Morgan Stanley, and Piper Sandler, with Stifel and Canaccord Genuity acting as co-managers.
Heartflow (NASDAQ: HTFL), an AI technology company focused on coronary artery disease (CAD), has announced the pricing of its upsized IPO. The company is offering 16,666,667 shares at $19.00 per share, expecting to raise approximately $316.7 million in gross proceeds.
Trading will commence on August 8, 2025, on the Nasdaq Global Select Market. The underwriters have a 30-day option to purchase up to 2.5 million additional shares. The IPO is expected to close on August 11, 2025, with J.P. Morgan, Morgan Stanley, and Piper Sandler serving as joint book-running managers.
Heartflow (NYSE:HTFL) announced that UnitedHealthcare, the largest commercial insurer in the United States, will provide nationwide coverage for its AI-enabled Heartflow Plaque Analysis across all business lines. The coverage, effective October 1, 2025, will include Commercial, Medicare Advantage, and Community plans.
The FDA-cleared technology, showing 95% agreement with gold standard IVUS, helps diagnose and manage coronary artery disease (CAD). Clinical outcomes from the DECIDE registry demonstrated that management changes guided by Heartflow Plaque Analysis resulted in an average LDL cholesterol decrease of 18.7mg/dL, associated with a 15% reduction in cardiac event risk.